39.89
-0.72(-1.77%)
Currency In USD
| Previous Close | 40.61 |
| Open | 40.61 |
| Day High | 40.8 |
| Day Low | 39.47 |
| 52-Week High | 42.18 |
| 52-Week Low | 14.59 |
| Volume | 293,494 |
| Average Volume | 406,017 |
| Market Cap | 1.16B |
| PE | -90.66 |
| EPS | -0.44 |
| Moving Average 50 Days | 36.43 |
| Moving Average 200 Days | 24.05 |
| Change | -0.72 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $1,864.02 as of January 09, 2026 at a share price of $39.89. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $521.3 as of January 09, 2026 at a share price of $39.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified careFRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanomaFRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving